电邮这篇文章 Resolution on the experts' discussion of the TRIANGLE study results
- 期: 卷 25, 编号 4 (2023)
- 页面: 415-416
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/252431
- DOI: https://doi.org/10.26442/18151434.2023.4.202535
- ID: 252431
如何引用文章
全文:
详细
On September 30, 2023, a discussion of the results of the European Community study on mantle cell lymphoma – TRIANGLE study was held in Moscow. The TRIANGLE phase III international randomized trial enrolled nearly 900 young subjects (up to 65 years of age) with histologically confirmed untreated mantle cell lymphoma in advanced stages II–IV. Study centers from 14 European countries participated in the study. According to the TRIANGLE study results, adding ibrutinib to autologous hematopoietic stem cell transplantation allows achieving a 3-year disease-free survival rate of 88%, which is significantly better than in the standard chemotherapy group.
参考
- Лимфома из клеток мантии. Клинические рекомендации. Современная Онкология. 2020;22(3):6-23 [Mantle cell lymphoma. Clinical recommendations. Journal of Modern Oncology. 2020;22(3):6-23 (in Russian)]. doi: 10.26442/18151434.2020.3.200377
- Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16. doi: 10.1056/NEJMoa1306220
- Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211-4. doi: 10.3324/haematol.2018.205229
- Dreyling M, Doorduijn JK, Gine E, et al; Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network. Blood. 2022;140(Suppl. 1):1-3. doi: 10.1182/blood-2022-163018
